

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONVENIENCE TRANSLATION INTO ENGLISH OF
CONSOLIDATED FINANCIAL STATEMENTS
AT 30 SEPTEMBER 2022**

(ORIGINALLY ISSUED IN TURKISH)

**CONVENIENCE TRANSLATION INTO ENGLISH OF THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY
ISSUED IN TURKISH**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AT 30 SEPTEMBER 2022 AND 31 DECEMBER 2021**

(Amounts expressed in thousands of Turkish Lira (“TRY”) unless otherwise indicated.)

| | 30 September 2022 USD (*) | 30 September 2022 TRY | <i>Audited</i> 31 December 2021 TRY |
|---|--|--------------------------------------|--|
| Notes | | | |
| Current assets | 366,383 | 6,784,944 | 6,028,316 |
| Cash and cash equivalents | 66,779 | 1,236,677 | 2,835,689 |
| Financial investments | 6,091 | 112,806 | - |
| Trade receivables | | | |
| - Due from unrelated parties | 69,797 | 1,292,545 | 686,910 |
| - Due from related parties | 72,396 | 1,340,675 | 455,902 |
| Other receivables | | | |
| - Due from unrelated parties | 60 | 1,118 | 1,013 |
| Derivative financial assets | 463 | 8,573 | 4,687 |
| Inventories | 111,545 | 2,065,661 | 1,559,041 |
| Prepayments | 3,596 | 66,594 | 126,669 |
| Current income tax assets | - | - | 3,447 |
| Other current asset | 35,656 | 660,295 | 352,817 |
| Assets held for sale | - | - | 2,141 |
| Non-current assets | 242,365 | 4,488,299 | 3,414,734 |
| Trade receivables | | | |
| - Due from unrelated parties | 4,948 | 91,624 | 141,461 |
| Derivative financial assets | 1,157 | 21,433 | 4,162 |
| Investment accounted for using equity method | 58,369 | 1,080,918 | 778,181 |
| Investment properties | 783 | 14,491 | 14,856 |
| Property, plant and equipment | 139,535 | 2,584,007 | 2,070,534 |
| Right of use assets | 1,815 | 33,626 | 35,796 |
| Intangible assets and goodwill | | | |
| - Goodwill | 323 | 5,989 | 5,989 |
| - Other intangible assets | 7,149 | 132,385 | 115,722 |
| Prepayments | 10,602 | 196,333 | 55,953 |
| Deferred tax asset | 17,684 | 327,493 | 192,080 |
| Total assets | 608,748 | 11,273,243 | 9,443,050 |

(*) United States Dollar (“USD”) amounts presented above have been translated from Turkish Lira (“TRY”) for convenience purposes only, at the official TRY bid rate announced by the Central Bank of the Republic of Turkey (“CBRT”) at 30 September 2022, and therefore do not form part of these interim condensed consolidated financial statements.

This interim condensed consolidated financial statements for the period ended 30 September 2022 have been approved for issue by the Board of Directors on 2 November 2022.

**CONVENIENCE TRANSLATION INTO ENGLISH OF THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY
ISSUED IN TURKISH**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
AT 30 SEPTEMBER 2022 AND 31 DECEMBER 2021**

(Amounts expressed in thousands of Turkish Lira (“TRY”) unless otherwise indicated.)

| | Notes | 30 September 2022 USD (*) | 30 September 2022 TRY | <i>Audited</i> 31 December 2021 TRY |
|--|-------|------------------------------|--------------------------|---|
| Current liabilities | | 300,086 | 5,557,196 | 5,908,199 |
| Current borrowings | | 84,155 | 1,558,434 | 2,125,952 |
| Current borrowings from unrelated parties | | | | |
| - Bank loans | | 18,922 | 350,417 | 227,640 |
| - Lease liabilities | | 629 | 11,640 | 10,692 |
| Trade payables | | | | |
| - Due to unrelated parties | | 164,946 | 3,054,577 | 3,068,942 |
| - Due to related parties | | 10,732 | 198,751 | 97,593 |
| Payables related to employee benefits | | 668 | 12,362 | 5,876 |
| Other payables | | | | |
| - Other payables to unrelated parties | | 2,259 | 41,851 | 28,752 |
| Deferred income other than contract liabilities | | 9,521 | 176,310 | 299,147 |
| Current tax liabilities | | 5,487 | 101,614 | - |
| Current provisions | | | | |
| - Current provisions for employee benefits | | 2,761 | 51,135 | 43,500 |
| - Other current provisions | | 6 | 105 | 105 |
| Non-current liabilities | | 67,873 | 1,256,930 | 700,572 |
| Long term borrowings | | | | |
| - Bank loans | | 58,502 | 1,083,378 | 565,315 |
| - Lease liabilities | | 2,403 | 44,509 | 45,297 |
| Non-current provisions | | | | |
| - Non-current provisions for employee benefits | | 4,991 | 92,429 | 59,750 |
| Other non-current liabilities | | 1,977 | 36,614 | 30,210 |
| Total liabilities | | 367,959 | 6,814,126 | 6,608,771 |
| EQUITY | | 240,790 | 4,459,117 | 2,834,279 |
| Equity attributable to owners of parent | | 240,790 | 4,459,117 | 2,834,279 |
| Issued capital | | 17,482 | 323,750 | 323,750 |
| Inflation adjustments on capital | | 3,048 | 56,469 | 56,469 |
| Treasury shares (-) | | | | |
| Share premium | | | | |
| Other accumulated comprehensive income/loss that will not be reclassified in profit or loss | | | | |
| - Gains/(losses) on remeasurement of defined benefit plans | | (2,769) | (51,281) | (30,237) |
| - Share of other comprehensive income of investments accounted for using equity method | | 641 | 11,865 | 9,585 |
| Other comprehensive income/loss that will be reclassified in profit or loss | | | | |
| - Exchange differences on translation | | 57,983 | 1,073,770 | 762,523 |
| - Gains/(losses) on hedge | | (23,044) | (426,754) | (319,200) |
| Restricted reserves appropriated from profits | | 16,975 | 314,349 | 256,074 |
| Prior years' profits or losses | | 60,377 | 1,118,102 | 608,107 |
| Current period net profit or loss | | 110,097 | 2,038,847 | 1,167,208 |
| Non-controlling interests | | - | - | - |
| Total liabilities and equity | | 608,749 | 11,273,243 | 9,443,050 |

(*) United States Dollar (“USD”) amounts presented above have been translated from Turkish Lira (“TRY”) for convenience purposes only, at the official TRY bid rate announced by the Central Bank of the Republic of Turkey (“CBRT”) at 30 September 2022, and therefore do not form part of these interim condensed consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY
ISSUED IN TURKISH**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME FOR THE INTERIM PERIODS ENDED
30 SEPTEMBER 2022 AND 2021**

(Amounts expressed in thousands of Turkish Lira (“TRY”) unless otherwise indicated.)

| Notes | <i>Not Reviewed</i> 1 January - 1 January - 30 September 2022 USD (*) | <i>Not Reviewed</i> 1 January - 1 January - 30 September 2022 TRY | <i>Not reviewed</i> 1 June - 30 September 2022 TRY | <i>Not Reviewed</i> 1 January - 30 September 2021 TRY | <i>Not reviewed</i> 1 June - 30 September 2021 TRY |
|--|--|--|---|--|---|
| Profit or loss | | | | | |
| Revenue | 829,399 | 13,144,068 | 4,884,609 | 5,300,787 | 2,233,069 |
| Cost of sales (-) | (617,617) | (9,787,804) | (3,592,605) | (4,260,746) | (1,794,177) |
| Gross profit (loss) | 211,782 | 3,356,264 | 1,292,004 | 1,040,041 | 438,892 |
| General administrative expenses (-) | (10,422) | (165,158) | (61,458) | (67,793) | (24,122) |
| Marketing expenses (-) | (14,310) | (226,786) | (87,732) | (95,101) | (39,550) |
| Research and development expenses (-) | (1,052) | (16,676) | (6,762) | (8,882) | (3,813) |
| Other income from operating activities | 93,936 | 1,488,663 | 238,033 | 315,337 | 60,280 |
| Other expense from operating activities (-) | (105,912) | (1,678,467) | (280,732) | (302,642) | (46,363) |
| Profit/(loss) from operating activities | 174,022 | 2,757,840 | 1,093,353 | 880,960 | 385,324 |
| Investment activity income | 3,355 | 53,175 | 19,664 | 15,646 | 10,850 |
| Share of profit (loss) from investments accounted for using equity method | (204) | (3,238) | 13,266 | 31,043 | 9,915 |
| Profit/(loss) before financing income/(expense) | 177,173 | 2,807,777 | 1,126,283 | 927,649 | 406,089.00 |
| Finance income | 25,507 | 404,222 | 87,639 | 236,125 | 84,447 |
| Finance costs (-) | (64,336) | (1,019,585) | (250,231) | (303,636) | (109,788) |
| Profit/(loss) from continuing operations, before tax | 138,344 | 2,192,414 | 963,691 | 860,138 | 380,748 |
| Tax (expense) / income continuing operations | | | | | |
| - Current period tax (expense)/income | (16,423) | (260,262) | (96,288) | (69,609) | (32,894) |
| - Deferred tax (expense)/income | 6,733 | 106,695 | 115,862 | (22,470) | (4,016) |
| Profit/(loss) from continuing operations | 128,654 | 2,038,847 | 983,265 | 768,059 | 343,838 |
| Attributable to: | | | | | |
| Owners of parent | 128,654 | 2,038,847 | 983,265 | 768,059 | 343,838 |
| Non-controlling interests | - | - | - | - | - |
| | 128,654 | 2,038,847 | 983,265 | 768,059 | 343,838 |
| Basic earnings/(loss) per share from continuing operations (Kr) | 0.40 | 6.30 | 3.04 | 2.37 | 1.86 |

(*) USD amounts presented above have been translated from TRY for convenience purposes only, at the USD average CBRT bid rates for the period ended 30 September 2022, and therefore do not form part of these interim condensed consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF THE INTERIM
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY
ISSUED IN TURKISH**

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2022**

(Amounts expressed in thousands of Turkish Lira (“TRY”) unless otherwise indicated.)

| Notes | <i>Not Reviewed</i> 1 January - 1 January - 30 September 2022 | | <i>Not reviewed</i> 1 June - 30 September 2022 | | <i>Not Reviewed</i> 1 January - 30 September 2021 | | <i>Not reviewed</i> 1 June - 30 September 2021 | |
|--|---|------------------|--|----------------|---|-----|--|-----|
| | USD (*) | TRY | TRY | TRY | TRY | TRY | TRY | TRY |
| Other comprehensive income | | | | | | | | |
| Other comprehensive income that will not be reclassified to profit or loss | | | | | | | | |
| Gains/(losses) on remeasurements of defined benefit plans | 144 | 2,280 | (63) | 1,390 | 140 | | | |
| Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss | | | | | | | | |
| - Gains/(losses) on remeasurement of defined benefit plans of associates and joint ventures accounted for using equity method | (1,660) | (26,305) | - | (3,287) | - | | | |
| Taxes relating to components of other comprehensive income that will not be reclassified to profit or loss | 332 | 5,261 | - | 657 | - | | | |
| Other comprehensive income that will be reclassified to profit or loss | | | | | | | | |
| Other comprehensive income/(loss) related with cash flow hedges | (8,231) | (130,443) | (73,331) | (88,207) | 3,474 | | | |
| Currency translation differences | 19,640 | 311,247 | 111,687 | 92,896 | 8,535 | | | |
| Taxes relating to other comprehensive income to be reclassified to profit or loss | 1,444 | 22,889 | 14,832 | 20,421 | (723) | | | |
| Total comprehensive income/(loss) | 140,323 | 2,223,776 | 1,036,390 | 791,929 | 355,264 | | | |
| Attributable to: | | | | | | | | |
| Owners of parent | 140,323 | 2,223,776 | 1,036,390 | 791,929 | 355,264 | | | |
| Non-controlling interests | - | - | - | - | - | | | |
| | 140,323 | 2,223,776 | 1,036,390 | 791,929 | 355,264 | | | |

(*) USD amounts presented above have been translated from TRY for convenience purposes only, at the USD average CBRT bid rates for the period ended 30 September 2022, and therefore do not form part of these interim condensed consolidated financial statements.